Very-low-calorie ketogenic diet as a safe and valuable tool for long-term glycemic management in patients with obesity and type 2 diabetes

Autor: Eleonora Moriconi, Massimiliano Caprio, Andrea Fabbri, Andrea Lenzi, Elisabetta Camajani
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Blood Glucose
Male
medicine.medical_specialty
obesity
medicine.medical_treatment
030209 endocrinology & metabolism
lcsh:TX341-641
Glycemic Control
Type 2 diabetes
eating behavior
Article
Management of obesity
03 medical and health sciences
0302 clinical medicine
Settore MED/13
Quality of life
Weight loss
Internal medicine
Weight Loss
medicine
VLCKD
diabetes remission
weight-loss
Humans
030212 general & internal medicine
Aged
Caloric Restriction
Retrospective Studies
Glycated Hemoglobin
Nutrition and Dietetics
business.industry
Retrospective cohort study
Feeding Behavior
Middle Aged
medicine.disease
Obesity
Metformin
Treatment Outcome
Diabetes Mellitus
Type 2
Quality of Life
Female
medicine.symptom
Diet
Ketogenic
business
lcsh:Nutrition. Foods and food supply
Food Science
medicine.drug
Ketogenic diet
Zdroj: Nutrients, Vol 13, Iss 758, p 758 (2021)
Nutrients
Volume 13
Issue 3
Popis: Obesity-related type 2 diabetes represents one of the most difficult challenges for the healthcare system. This retrospective study aims to determine the efficacy, safety and durability of a very-low-calorie ketogenic diet (VLCKD), compared to a standard low-calorie diet (LCD) on weight-loss, glycemic management, eating behavior and quality of life in patients with type 2 diabetes (T2DM) and obesity. Thirty patients with obesity and T2DM, aged between 35 and 75 years, who met the inclusion criteria and accepted to adhere to a VLCKD or a LCD nutritional program, were consecutively selected from our electronic database. Fifteen patients followed a structured VLCKD protocol, fifteen followed a classical LCD. At the beginning of the nutritional protocol, all patients were asked to stop any antidiabetic medications, with the exception of metformin. Data were collected at baseline and after 3 (T1) and 12 (T2) months. At T1 and T2, BMI was significantly reduced in the VLCKD group (p <
0.001), whereas it remained substantially unchanged in the LCD group. HbA1c was significantly reduced in the VLCKD group (p = 0.002), whereas a slight, although not significant, decrease was observed in the LCD group. Quality of life and eating behavior scores were improved in the VLCKD group, whereas no significant changes were reported in the LCD group, both at T1 and T2. At the end of the study, in the VLCKD group 26.6% of patients had stopped all antidiabetic medications, and 73.3% were taking only metformin, whereas 46.6% of LCD patients had to increase antidiabetic medications. The study confirms a valuable therapeutic effect of VLCKD in the long-term management of obesity and T2DM and its potential contribution to remission of the disease.
Databáze: OpenAIRE
Externí odkaz: